These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Sanders S; Harisdangkul V Am J Med Sci; 2002 Apr; 323(4):190-3. PubMed ID: 12003373 [TBL] [Abstract][Full Text] [Related]
3. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Herrmann ML; Schleyerbach R; Kirschbaum BJ Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294 [TBL] [Abstract][Full Text] [Related]
4. [Leflunomide--a new drug for pharmacological immunomodulation]. Wozel G; Pfeiffer C Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action for leflunomide in rheumatoid arthritis. Fox RI; Herrmann ML; Frangou CG; Wahl GM; Morris RE; Strand V; Kirschbaum BJ Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330 [TBL] [Abstract][Full Text] [Related]
6. Leflunomide in dermatology. Boyd AS J Am Acad Dermatol; 2012 Apr; 66(4):673-9. PubMed ID: 21962758 [TBL] [Abstract][Full Text] [Related]
7. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. Leban J; Vitt D Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448 [TBL] [Abstract][Full Text] [Related]
8. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of leflunomide in rheumatoid arthritis. Fox RI J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414 [TBL] [Abstract][Full Text] [Related]
11. Leflunomide for rheumatoid arthritis. Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115 [TBL] [Abstract][Full Text] [Related]
12. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Smolen JS; Graninger WB; Emery P Rheumatology (Oxford); 2000 Jul; 39(7):689-92. PubMed ID: 10908683 [No Abstract] [Full Text] [Related]
13. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Mroczkowski PJ; Weinblatt ME; Kremer JM Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S66-8. PubMed ID: 10589360 [TBL] [Abstract][Full Text] [Related]
14. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303 [TBL] [Abstract][Full Text] [Related]
15. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug. Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of leflunomide]. Hirohata S Nihon Rinsho; 2002 Dec; 60(12):2357-63. PubMed ID: 12510362 [TBL] [Abstract][Full Text] [Related]
18. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Breedveld FC; Dayer JM Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058 [TBL] [Abstract][Full Text] [Related]
19. Leflunomide: a drug with a potential beyond rheumatology. Teschner S; Burst V Immunotherapy; 2010 Sep; 2(5):637-50. PubMed ID: 20874647 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Greene S; Watanabe K; Braatz-Trulson J; Lou L Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]